NRAS and chronic myelomonocytic leukemia: Moreover, the confirmatory role of ASXL1 and NRAS mutations in influencing CMML prognosis, consistent with broader literature, emphasizes the potential of targeted therapies and highlights the need for enhanced predictive tools.